• GSK343 and the Epigenetic-Repair Nexus: Charting a New Co...

  2025-10-18

  This thought-leadership article dissects the mechanistic underpinnings and strategic opportunities surrounding GSK343, a potent, selective, and cell-permeable EZH2 inhibitor. Moving beyond conventional narratives, we bridge the PRC2/H3K27 trimethylation axis with the latest discoveries on DNA repair and telomerase (TERT) regulation—most notably the pivotal role of APEX2. Translational researchers will find actionable guidance for experimental design, validation, and clinical translation, as well as a roadmap for leveraging GSK343 to unravel the complexities of epigenetic and repair-driven oncogenesis.

• STING Pathway Activation: Mechanistic Insights and Strate...

  2025-10-17

  Explore how small molecule STING pathway activators, exemplified by STING agonist-1, are reshaping translational immunology and oncology research. This thought-leadership article unpacks the mechanistic interplay between STING, CD40, and TRAF2 in B-cell-driven antitumor immunity—anchored in breakthrough findings from esophageal squamous cell carcinoma research—and offers strategic guidance for harnessing these insights in experimental and therapeutic development.

182 records 13/13 page Previous First page 上5页 111213